BioSig Technologies (OTCQB: BSGM) said today it will engage in an institutional investor roadshow in the EU as it seeks funding for its proprietary Pure electrophysiology platform.
The company is developing a cardiac signal acquisition and display system which is designed to assist electrophysiologists in making clinical decisions for patients with abnormal heart rates and rhythms, including atrial fibrillation and ventricular tachycardia.
Minneapolis, Minn.-based BioSig said it will tour “major EU financial centers” between Feb. 27 and March 3, with board chair Kenneth Londoner delivering presentations and meeting 1-on-1 in London, Zurich, Geneva, Paris and Milan.
“Our company is proceeding with European regulatory clearance for the Pure EP System and we will continue to build commercial and investor relationships in the EU prior to launch,” Londoner said in a press release.
Earlier this month, BioSig issued a letter to its shareholders updating them on the company’s recent developments and revealing that it tapped Minnetronix to develop the 1st version of its Pure EP system.
